“ILIAS Biologics Inc. plans to begin a clinical trial for new exosome-based therapeutics in Australia around September.”

Chulhee Choi, Co-CEO of ILIAS, said in an interview with Hankyung.

ILIAS submitted a phase 1 clinical trial plan (IND) of the lead pipeline, ‘ILB-202’, to the Australian Food and Drug Administration (TGA) in February. The first clinical trial as exosome-based therapeutics in Korea is expected.

Please find the link below for the full article.

Interview Link(Kor.)